Role of anti-vimentin antibodies in renal transplantation

Transplantation

Volumn 98, Issue 1, 2014, Pages 72-78

  Besarani, Dler ^a,b   Cerundolo, Lucia ^b   Smith, John D ^c   Procter, Jeanette ^a   Barnardo, Martin C N ^a   Roberts, Ian S D ^a   Friend, Peter J ^a,b   Rose, Marlene L ^c   Fuggle, Susan V ^a,b  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Anti vimentin antibodies; HLA antibodies; Interstitial fibrosis and tubular atrophy; Non HLA antibodies; Renal transplantation

Indexed keywords

HLA ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; UNCLASSIFIED DRUG; VIMENTIN; VIMENTIN ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSING ALVEOLITIS; GRAFT RECIPIENT; HUMAN; KIDNEY ALLOGRAFT; KIDNEY HYPERTROPHY; KIDNEY TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; RETROSPECTIVE STUDY;

ADULT; ATROPHY; BIOPSY; FEMALE; FIBROSIS; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; ISOANTIBODIES; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIMENTIN;

EID: 84903706007     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000443224.66960.37     Document Type: Article

References (35)

1. Smith JD, Hamour IM, Banner NR, et al. C4d fixing, luminex binding antibodies-a new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7: 2809.
2. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 2011; 11: 312.
3. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004; 4: 438.
4. Fedoseyeva EV, Zhang F, Orr PL, et al. De novo autoimmunity to cardiac myosin after heart transplantation and its contribution to the rejection process. J Immunol 1999; 162: 6836.
5. Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365: 1570.
6. Rose ML. Role of MHC and non-MHC alloantibodies in graft rejection. Curr Opinion Organ Transplantation 2004; 9: 16.
7. Sumitran-Holgersson S,Wilczek HE, Holgersson J, et al. Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 2002; 74: 268.
8. Warraich RS, Pomerance A, Stanley A, et al. Cardiac myosin autoantibodies and acute rejection after heart transplantation in patients with dilated cardiomyopathy. Transplantation 2000; 69: 1609.
9. Haque MA, Mizobuchi T, Yasufuku K, et al. Evidence for immune responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection. J Immunol 2002; 169: 1542.
10. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558.
11. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71: 886.
12. Win TS, Rehakova S, Negus MC, et al. Donor CD4 T cells contribute to cardiac allograft vasculopathy by providing help for autoantibody production. Circ Heart Fail 2009; 2: 361.
13. Nakanishi K, Maruyama M, Shibata T, et al. Identification of a caspase-9 substrate and detection of its cleavage in programmed cell death during mouse development. J Biol Chem 2001; 276: 41237.
14. Moisan E, Girard D. Cell surface expression of intermediate filament proteins vimentin and lamin B1 in human neutrophil spontaneous apoptosis. J Leukoc Biol 2006; 79: 489.
15. Azimzadeh AM, Pfeiffer S, Wu GS, et al. Humoral immunity to vimentin is associated with cardiac allograft injury in nonhuman primates. Am J Transplant 2005; 5: 2349.
16. Jonker M, Danskine A, Haanstra K, et al. The autoimmune response to vimentin after renal transplantation in nonhuman primates is immunosuppression dependent. Transplantation 2005; 80: 385.
17. Carter V, Shenton BK, Jaques B, et al. Vimentin antibodies: a non- HLA antibody as a potential risk factor in renal transplantation. Transplant Proc 2005; 37: 654.
18. Mi H, Carter V, Gupta A, et al. Anti-vimentin antibody detection in recipients of heart-beating and non-heart beating donor kidneys. Transplant Proc 2005; 37: 3269.
19. Boros P, Bromberg JS. New cellular and molecular immune pathways in ischemia/reperfusion injury. Am J Transplant 2006; 6: 652.
20. Leong HS, Mahesh BM, Day JR, et al. Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor. J Leukoc Biol 2008; 83: 263.
21. Podor TJ, Singh D, Chindemi P, et al. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. J Biol Chem 2002; 277: 7529.
22. Boilard E, Bourgoin SG, Bernatchez C, et al. Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2. Blood 2003; 102: 2901.
23. Mor-Vaknin N, Punturieri A, Sitwala K, et al. Vimentin is secreted by activated macrophages. Nat Cell Biol 2003; 5: 59.
24. Mahoney JA, Rosen A. Apoptosis and autoimmunity. Curr Opin Immunol 2005; 17: 583.
25. Barber LD, Whitelegg A, Madrigal JA, et al. Detection of vimentinspecific autoreactive CD8+ T cells in cardiac transplant patients. Transplantation 2004; 77: 1604.
26. Ohsaki H, Hirakawa E, Nakamura M, et al. Expression of vimentin and high-molecular-weight cytokeratin (clone 34ssE12) in differentiating reactive renal tubular cells from low-grade urothelial carcinoma cells in voided urine. Cytopathology 2011; 22: 247.
27. Vansthertem D, Gossiaux A, Decleves AE, et al. Expression of nestin, vimentin, and NCAM by renal interstitial cells after ischemic tubular injury. J Biomed Biotechnol 2010; 2010: 193259.
28. Bilalic S, Veitinger M, Ahrer KH, et al. Identification of Non-HLA antigens targeted by alloreactive antibodies in patients undergoing chronic hemodialysis. J Proteome Res 2010; 9: 1041.
29. Bilalic S, Michlmayr A, Gruber V, et al. Lymphocyte activation induces cell surface expression of an immunogenic vimentin isoform. Transpl Immunol 2012; 27: 101.
30. Mahesh B, Leong HS, McCormack A, et al. Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am J Pathol 2007; 170: 1415.
31. Mahesh B, Leong HS, Nair KS, et al. Autoimmunity to vimentin potentiates graft vasculopathy in murine cardiac allografts. Transplantation 2010; 90: 4.
32. Nath DS, Ilias BH, Tiriveedhi V, et al. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy. J Heart Lung Transplant 2010; 29: 1277.
33. Worthington JE, Martin S, Al Husseini DM, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1034.
34. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
35. Sutton PM, Harmer AH, Bayne AM, et al. The flow cytometric detection of alloantibodies in screening for renal transplantation. Transpl Int 1995; 8: 360.